Opening Remarks from Dr. Herzog, Dr. Krivak, and Dr. Hagemann

Author(s):

Thomas J. Herzog, MD,Thomas C. Krivak, MD

Thomas Herzog, MD, Thomas Krivak, MD, and Ian Hagemann, MD, PhD open their discussion by introducing themselves and the objectives of the program.

Now Viewing

EP: 1.Opening Remarks from Dr. Herzog, Dr. Krivak, and Dr. Hagemann

EP: 2.Defining HRD and its Role in Ovarian Cancer

EP: 3.Other Causes of HRD: Chromosomal LOH, LST, and TAI

EP: 4.Commercially Available  HRD Tests for Ovarian Cancer

EP: 5.Leveraging HRD Testing Results in Ovarian Cancer: Clinical Data

EP: 6.HRD Testing in Ovarian Cancer: Clinical Guidelines Recommendations

Dr. Thomas Herzog: Greetings, welcome to Optimizing Homologous Recombination Deficiency Testing Paradigms in Ovarian Cancer. So our objectives tonight are to define what HRD is from a multidisciplinary perspective and how it relates to ovarian cancer development and disease progression. We also want to discuss the similarities and differences between somatic and germline, homologous recombination deficiency testing, sampling considerations and available methodologies and products, as well as how this all affects treatment decisions. We want to review how changes in the treatment landscape have affected HRD testing paradigms. And finally, we want to share best practices and clinical insight into how and when PR providers should order HRD testing for their patients with ovarian cancer. I'm Dr. Tom Herzog. I'm deputy director at the University of Cincinnati Cancer Center. And joining me tonight are two of my esteemed colleagues, and I'm going to have them both introduce themselves Dr. Krivak, and we're going to probably call each other by first name. It's not to be pejorative, but rather because friends, so we just if we're informal, that's why. Tom.

Dr. Thomas Krivak: I agree. Tom, we're all friends here and thanks for the, the excellent introduction. My name's Tom Krivak, GY oncologist and director of GY oncology research, as well as the division at Allegheny Health Network in Pittsburgh Pennsylvania. So thanks for having me on board. It's good to do this discussion.

Dr. Thomas Herzog: Great. And Ian?

Dr. Ian Hagemann: Hi everyone. Uh, my name is Ian Hagerman. Uh, I'm a pathologist at Washington University in St. Louis, Missouri. Uh, my main areas of interest are gynecologic breast and molecular pathology. So I'm here to represent the laboratory perspective as we talk about homologous recombination deficiency testing, and really appreciate the chance to be here.

Dr. Thomas Herzog: I'm really excited to have both of you with us and hopefully we'll be able to have a spirited dialogue that I think will be to the benefit of our audience in terms of learning opportunities.